FDA advisers endorse mRNA flu vaccine. What is the takeaway?

Helen Branswell covers points broadly associated to infectious ailments, together with outbreaks, preparedness, analysis, and vaccine growth. Observe her on Mastodon and Bluesky. You possibly can attain Helen on Sign at hbranswell.01.

A panel of advisers to the Meals and Drug Administration gave its endorsement Thursday to a seasonal mRNA flu vaccine that was developed by Moderna and that earlier this 12 months turned the topic of controversy when a high company official briefly refused to even contemplate accepting it for assessment.

The Vaccines and Associated Organic Merchandise Advisory Committee — generally known as VRBPAC — voted unanimously that the advantages of the vaccine outweigh the dangers for each adults ages 50 to 64, and people 65 and older. It stays to be seen what the FDA will determine, however workers displays in the course of the assembly instructed the company sees the vaccine as having cleared enough hurdles to be licensed by way of a standard pathway for the youthful group, and an accelerated pathway for the older group. 

A number of flu vaccines at the moment available on the market had been first licensed utilizing an accelerated pathway, Wellington Solar, a former FDA worker, famous in the course of the assembly’s public remark interval. (After leaving FDA, Solar labored for Moderna, however he’s now not with the corporate.)